Osteoporosis. Osteoporosis with current pathological fracture
Conditions
Interventions
Intervention group: After performing a bone density test and assuring osteoporosis, the person will receive a 60 mg dose of denosumab(Xgeva®, produced by Amgen ) subcutaneously at baseline and 6 month
Sponsors
Artesh University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: Postmenopausal women (aged 45 to 75 years old) diagnosed with osteoporosis by densitometry via Dexa(dual energy Xray absorptiometry).
Exclusion criteria
Exclusion criteria: Lack of consent for being in the trial Having hypersensitivity to denosumab or any component in the formulation Malabsorption syndrome History of thyroid surgery, parathyroid surgery or intestinal resection which has been caused malabsorption Patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage change in Bone mineral density(BMD) at the lumbar spine (L1-L4), femoral neck, and total hip. Timepoint: Baseline and at 12th month of the study. Method of measurement: BMD by dual-energy x-ray absorptiometry Hologic 4500 or higher. | — |
Secondary
| Measure | Time frame |
|---|---|
| (T score). Timepoint: At the beginning of the study and12 months later. Method of measurement: Bone densitometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohsen Ghasemzadeh Soroush
Artesh University of Medical Sciences
Outcome results
None listed